Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution
BackgroundAcute MyeloidLeukemia is a clonal malignant disease, whit disappointing cure rates withcurrent treatment options. The authors’ intent to characterise acute myeloidleukaemia patients and to evaluate the outcome gain associated with the use ofantagonists of P-glycoprotein in induction regime...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1780 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059511110303744 |
|---|---|
| author | Ana Espirito Santo Sergio Chacim Luis Leite Isabel Cristina Claudia Moreira Dulcineia Pereira Margarida Dantas Marta Nunes Luisa Viterbo Angelo Martins Ilidia Moreira Isabel Oliveira Nelson Domingues Jose Mario Mariz Rui Medeiros |
| author_facet | Ana Espirito Santo Sergio Chacim Luis Leite Isabel Cristina Claudia Moreira Dulcineia Pereira Margarida Dantas Marta Nunes Luisa Viterbo Angelo Martins Ilidia Moreira Isabel Oliveira Nelson Domingues Jose Mario Mariz Rui Medeiros |
| author_sort | Ana Espirito Santo |
| collection | DOAJ |
| description | BackgroundAcute MyeloidLeukemia is a clonal malignant disease, whit disappointing cure rates withcurrent treatment options. The authors’ intent to characterise acute myeloidleukaemia patients and to evaluate the outcome gain associated with the use ofantagonists of P-glycoprotein in induction regimens.Patients andmethodsThe authorsgathered the epidemiological features, disease traits and outcome of 185patients, diagnosed with Acute Myeloid Leukemia (AML), treated at InstitutoPortuguês de Oncologia – Porto, Portugal, since 1998 until December 2010. Patients can betreated according to two possible schemes: “SWOG 9126” (cytarabine,daunorubicin and cyclosporine) regimen used when dysplastic changes are presentor “idarubicin and cytarabine” performed on the remaining ones. ResultsSome importantdifferences were found in relevant clinical features in both groups (age,disease classification) that can influence outcome. Nevertheless the two groupsoverlap in other also prognostic relevant traits (cytogenetic, riskstratification).Overall survivaland disease free survival were assessed: relevant differences were found,favouring the use of “idarubicin and cytarabine” protocol over “SWOG 9126”protocol.In the presenceof secondary leukemia or previous myelodysplasia no gain was achieved with theuse of SWOG 9126.ConclusionThe authorsdemonstrate the lack of gain in OS associated to the use of “SWOG 9126”treatment when compared to “idarubicin and cytarabine” regimen, with moreprofound and long lasting responses in the latter that the ones achieved withthe use of SWOG 9126. This reducedefficacy is also encountered when dysplastic changes are met. |
| format | Article |
| id | doaj-art-61207fc73e494a019fcb9235cbeeec25 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-61207fc73e494a019fcb9235cbeeec252025-08-20T02:50:52ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institutionAna Espirito Santo0Sergio Chacim1Luis Leite2Isabel Cristina3Claudia Moreira4Dulcineia Pereira5Margarida Dantas6Marta Nunes7Luisa Viterbo8Angelo Martins9Ilidia Moreira10Isabel Oliveira11Nelson Domingues12Jose Mario Mariz13Rui Medeiros14Onco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalOnco-Hematology Department, IPO-Porto, PortugalMolecular Oncology, IPO-Porto, PortugalBackgroundAcute MyeloidLeukemia is a clonal malignant disease, whit disappointing cure rates withcurrent treatment options. The authors’ intent to characterise acute myeloidleukaemia patients and to evaluate the outcome gain associated with the use ofantagonists of P-glycoprotein in induction regimens.Patients andmethodsThe authorsgathered the epidemiological features, disease traits and outcome of 185patients, diagnosed with Acute Myeloid Leukemia (AML), treated at InstitutoPortuguês de Oncologia – Porto, Portugal, since 1998 until December 2010. Patients can betreated according to two possible schemes: “SWOG 9126” (cytarabine,daunorubicin and cyclosporine) regimen used when dysplastic changes are presentor “idarubicin and cytarabine” performed on the remaining ones. ResultsSome importantdifferences were found in relevant clinical features in both groups (age,disease classification) that can influence outcome. Nevertheless the two groupsoverlap in other also prognostic relevant traits (cytogenetic, riskstratification).Overall survivaland disease free survival were assessed: relevant differences were found,favouring the use of “idarubicin and cytarabine” protocol over “SWOG 9126”protocol.In the presenceof secondary leukemia or previous myelodysplasia no gain was achieved with theuse of SWOG 9126.ConclusionThe authorsdemonstrate the lack of gain in OS associated to the use of “SWOG 9126”treatment when compared to “idarubicin and cytarabine” regimen, with moreprofound and long lasting responses in the latter that the ones achieved withthe use of SWOG 9126. This reducedefficacy is also encountered when dysplastic changes are met.https://mjhid.org/index.php/mjhid/article/view/1780Acute myeloid leukemiatreatmentcyclosporinep glycoproteinoutcome |
| spellingShingle | Ana Espirito Santo Sergio Chacim Luis Leite Isabel Cristina Claudia Moreira Dulcineia Pereira Margarida Dantas Marta Nunes Luisa Viterbo Angelo Martins Ilidia Moreira Isabel Oliveira Nelson Domingues Jose Mario Mariz Rui Medeiros Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution Mediterranean Journal of Hematology and Infectious Diseases Acute myeloid leukemia treatment cyclosporine p glycoprotein outcome |
| title | Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution |
| title_full | Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution |
| title_fullStr | Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution |
| title_full_unstemmed | Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution |
| title_short | Therapeutic strategy in acute myeloid leukemia – the experience of a single Portuguese institution |
| title_sort | therapeutic strategy in acute myeloid leukemia the experience of a single portuguese institution |
| topic | Acute myeloid leukemia treatment cyclosporine p glycoprotein outcome |
| url | https://mjhid.org/index.php/mjhid/article/view/1780 |
| work_keys_str_mv | AT anaespiritosanto therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT sergiochacim therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT luisleite therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT isabelcristina therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT claudiamoreira therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT dulcineiapereira therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT margaridadantas therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT martanunes therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT luisaviterbo therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT angelomartins therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT ilidiamoreira therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT isabeloliveira therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT nelsondomingues therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT josemariomariz therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution AT ruimedeiros therapeuticstrategyinacutemyeloidleukemiatheexperienceofasingleportugueseinstitution |